Armata Pharmaceuticals Inc (ARMP)

2026-05-13T21:41:15.000Z - 22 days ago

Armata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year

May 13, 2026, 4:30 PM EDT - 22 days ago

Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

2026-05-07T13:17:19.000Z - 4 weeks ago

Armata Pharmaceuticals secures FDA Fast Track Designation for AP-SA02

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

May 4, 2026, 7:00 AM EDT - 4 weeks ago

Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"

Apr 27, 2026, 7:00 AM EDT - 5 weeks ago

Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.

2026-04-08T12:58:05.000Z - 2 months ago

Armata Pharmaceuticals price target raised to $20 from $15 at JonesResearch

2026-03-25T20:16:54.000Z - 2 months ago

Armata Pharmaceuticals reports Q4 EPS ($3.42) vs. (23c) last year

Mar 25, 2026, 4:05 PM EDT - 2 months ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

2026-03-19T11:15:28.000Z - 2 months ago

Armata Pharmaceuticals delays announcement of Q4, FY25 results

Mar 19, 2026, 7:00 AM EDT - 2 months ago

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

2026-02-23T14:38:12.000Z - 3 months ago

Armata price target raised to $15 from $9 at H.C. Wainwright

2026-02-23T12:11:05.000Z - 3 months ago

Armata Pharmaceuticals receives FDA QIDP designation for AP-SA02

Feb 23, 2026, 7:00 AM EST - 3 months ago

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

2026-01-13T12:06:02.000Z - 5 months ago

Armata Pharmaceuticals announces End-of-Phase 2 meeting with FDA

Jan 13, 2026, 7:00 AM EST - 5 months ago

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

2026-01-05T12:15:27.000Z - 5 months ago

Armata Pharmaceuticals initiated with a Buy at JonesResearch

Nov 18, 2025, 7:00 AM EST - 7 months ago

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

2025-11-12T21:10:57.000Z - 7 months ago

Armata Pharmaceuticals reports Q3 EPS (74c) vs. (15c) last year

Nov 12, 2025, 4:05 PM EST - 7 months ago

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

2025-11-10T15:15:34.000Z - 7 months ago

Armata Pharmaceuticals trading resumes

2025-11-10T15:11:07.000Z - 7 months ago

Armata Pharmaceuticals trading halted, volatility trading pause

2025-11-10T12:25:42.000Z - 7 months ago

Armata announces comissioning of cGMP manufacturing facility in Los Angeles

Nov 10, 2025, 7:00 AM EST - 7 months ago

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

2025-10-22T19:53:58.000Z - 8 months ago

Here’s Why Armata Pharmaceuticals Stock (ARMP) Exploded 300% Today

2025-10-22T15:40:10.000Z - 8 months ago

Armata data support advancing AP-SA02 to Phase 3, says H.C. Wainwright

2025-10-22T15:35:16.000Z - 8 months ago

Armata Pharmaceuticals up 19% after reporting results of diSArm study

2025-10-22T15:30:10.000Z - 8 months ago

Armata Pharmaceuticals trading resumes

2025-10-22T15:15:09.000Z - 8 months ago

Armata says diSArm study confirms efficacy of intravenous phage therapy for SAB

Oct 22, 2025, 11:10 AM EDT - 8 months ago

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

2025-10-22T14:35:09.000Z - 8 months ago

Armata Pharmaceuticals trading halted, news pending

Oct 14, 2025, 7:00 AM EDT - 8 months ago

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

2025-09-08T11:10:58.000Z - 9 months ago

Armata Pharmaceuticals announces publication on phage Pa223

Sep 8, 2025, 7:00 AM EDT - 9 months ago

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Sep 4, 2025, 7:00 AM EDT - 9 months ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 10 months ago

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

May 19, 2025, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

May 14, 2025, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

May 1, 2025, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Mar 20, 2025, 5:56 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Mar 12, 2025, 5:08 PM EDT - 1 year ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

INVA

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Dec 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Nov 13, 2024, 4:05 PM EST - 1 year ago

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Nov 12, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Structural Biology Publication

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Aug 15, 2024, 4:45 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Jul 30, 2024, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Jul 11, 2024, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Jul 10, 2024, 4:05 PM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

May 7, 2024, 4:01 PM EDT - 2 years ago

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Mar 4, 2024, 4:01 PM EST - 2 years ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

INVA

Feb 21, 2024, 7:00 AM EST - 2 years ago

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Nov 14, 2023, 4:00 PM EST - 2 years ago

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

May 31, 2023, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

May 11, 2023, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

Mar 6, 2023, 6:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Jan 10, 2023, 4:05 PM EST - 3 years ago

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

INVA

Dec 22, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection